SIGA Technologies Inc logo

SIGA - SIGA Technologies Inc News Story

$7.27 -0.1  -1.8%

Last Trade - 15/01/21

Sector
Healthcare
Size
Mid Cap
Market Cap £414.2m
Enterprise Value £356.3m
Revenue £67.3m
Position in Universe 3180th / 6547

SIGA Technologies to Host Business Update Call on November 5, 2020 Following Release of Third Quarter Financial Results

Thu 29th October, 2020 11:30am
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201029:nGNX4v8mQx


NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA)
(NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the
health security market, today announced that management will host a webcast
and conference call to provide a business update at 4:30 P.M. ET on Thursday,
November 5, 2020. Participating on the call will be Dr. Phil Gomez, Chief
Executive Officer, and Daniel Luckshire, Chief Financial Officer.

A live webcast of the call will be available on the Company's website at
www.siga.com under the 'Events & Presentations' tab in the Investor Relations
section, or by clicking here
(https://www.globenewswire.com/Tracker?data=2GaTJcCjZaB8Kw8KfLFa1WwMB4PTgxRSAlBP_sOojFUAIc_YaTPDlJjMJOXPs3zi4epOuBTCDIk83uxFzSfKhGJdK_sTec9GyyPJ339TBG99ueiPRY4_QvPuWklqdxN0_wjis0yccrc8NOfHs5Doo8BHJPlVYBKzaJN7V3GN4Eg=).
Participants may also access the call, by dialing 877-407-6184 for domestic
callers or 201-389-0877 for international callers. Please log in approximately
5-10 minutes prior to the scheduled start time.

A replay of the call will be available for two weeks by dialing 877-660-6853
for domestic callers or 201-612-7415 for international callers and using
Conference ID: 13711770. The archived webcast will be available in the Events
and Presentations section of the company's website
(https://www.globenewswire.com/Tracker?data=i9QbOyUE4Dcn5ZH5RWE3weUJDQf_qtNK-8cCanWzVwAr4Af-SDKLdWz1THQ8zZj4J6pEkc07QzQRwCEGTUGe6s1ky-3rDBjDVH5jWFyEQ46Temd47lQINHTFOdJVdDJb).

ABOUT SIGA TECHNOLOGIES, INC. and TPOXX(®)

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused
on the health security market. Health security comprises countermeasures for
biological, chemical, radiological and nuclear attacks (biodefense market),
vaccines and therapies for emerging infectious diseases, and health
preparedness. Our lead product is TPOXX®, also known as tecovirimat and
ST-246®, an orally administered and IV formulation antiviral drug for the
treatment of human smallpox disease caused by variola virus. TPOXX is a novel
small-molecule drug and the US maintains a stockpile of 1.7 million oral
courses in the Strategic National Stockpile under Project BioShield. The oral
formulation of TPOXX was approved by the FDA for the treatment of smallpox on
July 13, 2018. In September 2018, SIGA signed a contract with Biomedical
Advanced Research and Development Authority (BARDA) for additional procurement
and development related to both oral and intravenous formulations of TPOXX.
For more information about SIGA, please visit www.siga.com.

About Smallpox(1)

Smallpox is a contagious, disfiguring and often deadly disease that has
affected humans for thousands of years. Naturally occurring smallpox was
eradicated worldwide by 1980, the result of an unprecedented global
immunization campaign. Samples of smallpox virus have been kept for research
purposes. This has led to concerns that smallpox could someday be used as a
biological warfare agent. A vaccine can prevent smallpox, but the risk of the
current vaccine's side effects is too high to justify routine vaccination for
people at low risk of exposure to the smallpox virus.

FORWARD-LOOKING STATEMENTS

This press release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended.
Such forward-looking statements are subject to various known and unknown risks
and uncertainties, and SIGA cautions you that any forward-looking
information provided by or on behalf of SIGA is not a guarantee of future
performance. More detailed information about SIGA and risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release, is set forth
in SIGA's filings with the Securities and Exchange Commission,
including SIGA's Annual Report on Form 10-K for the fiscal year
ended December 31, 2019, and in other documents that SIGA has filed with
the SEC. SIGA urges investors and security holders to read those documents
free of charge at the SEC's web site at http://www.sec.gov. Interested
parties may also obtain those documents free of charge from SIGA.
Forward-looking statements are current only as of the date on which such
statements were made, and except for our ongoing obligations
under the United States of America federal securities laws, we undertake
no obligation to update publicly any forward-looking statements whether as a
result of new information, future events, or otherwise.

The information contained in this press release does not necessarily reflect
the position or the policy of the Government and no official endorsement
should be inferred.

Contacts:

Investors
David Carey
212-867-1768
david.carey@finnpartners.com

Media
Stephanie Seiler
206-713-0124
stephanie.seiler@finnpartners.com

(_________________1) http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769  

(https://www.globenewswire.com/NewsRoom/AttachmentNg/f6bb4557-ff79-4aa8-88ef-c41de9ffd198)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.